Literature DB >> 23393178

Effects of a high-protein diet on regulation of phosphorus homeostasis.

Robin A Kremsdorf1, Andrew N Hoofnagle, Mario Kratz, David S Weigle, Holly S Callahan, Jonathan Q Purnell, Angela M Horgan, Ian H de Boer, Bryan R Kestenbaum.   

Abstract

CONTEXT: High-protein diets, which are popular for weight loss, contain large quantities of phosphorus. Phosphorus excess and consequent changes in phosphorus regulatory hormones are implicated in vascular calcification and cardiovascular disease.
OBJECTIVE: We tested the hypothesis that a moderate increase in dietary phosphorus during a high-protein diet leads to changes in phosphorus-responsive hormones. DESIGN, PARTICIPANTS, AND
SETTING: We conducted a post hoc analysis of a sequential dietary modification trial in 19 healthy volunteers in the general community. INTERVENTION: Participants received 2 weeks of a weight-maintaining, low-protein (15%) diet, followed by 2 weeks of an isocaloric, high-protein (30%) diet, followed by 12 weeks of an ad libitum high-protein (30%) diet. MAIN OUTCOME MEASURES: Using previously collected samples, plasma concentrations of fibroblast growth factor-23 (FGF-23), PTH, 1,25-dihydroxyvitamin D, and 24,25-dihydroxyvitamin D were measured at 8 time points to assess 24-hour variability and in 24-hour pooled samples to delineate changes at the end of each diet period.
RESULTS: Mean dietary phosphorus intake during each study period was 1556, 2071, and 1622 mg/d, respectively. Plasma concentrations of FGF-23 and vitamin D metabolites varied in a diurnal pattern; plasma PTH concentrations varied in a bimodal pattern. After changing from a low- to high-protein isocaloric diet, plasma FGF-23 concentrations decreased slightly (mean -4.48 pg/mL, 95% confidence interval 1.88-7.07). There were no other statistically significant changes in phosphorus regulatory hormones in response to diet modifications.
CONCLUSIONS: Among healthy people, an approximate 33% increase in dietary phosphorus after institution of a high-protein diet does not cause large changes in measured concentrations of phosphorus regulatory hormones.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23393178      PMCID: PMC3590482          DOI: 10.1210/jc.2012-2910

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  29 in total

1.  Effects of dietary phosphate and calcium intake on fibroblast growth factor-23.

Authors:  Marc G Vervloet; Frans J van Ittersum; Rahel M Büttler; Annemieke C Heijboer; Marinus A Blankenstein; Piet M ter Wee
Journal:  Clin J Am Soc Nephrol       Date:  2010-10-28       Impact factor: 8.237

2.  The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study.

Authors:  Benjamin D Parker; Leon J Schurgers; Vincent M Brandenburg; Robert H Christenson; Cees Vermeer; Markus Ketteler; Michael G Shlipak; Mary A Whooley; Joachim H Ix
Journal:  Ann Intern Med       Date:  2010-05-18       Impact factor: 25.391

Review 3.  Protein, weight management, and satiety.

Authors:  Douglas Paddon-Jones; Eric Westman; Richard D Mattes; Robert R Wolfe; Arne Astrup; Margriet Westerterp-Plantenga
Journal:  Am J Clin Nutr       Date:  2008-05       Impact factor: 7.045

4.  Relations of serum phosphorus levels to echocardiographic left ventricular mass and incidence of heart failure in the community.

Authors:  Ravi Dhingra; Philimon Gona; Emelia J Benjamin; Thomas J Wang; Jayashri Aragam; Ralph B D'Agostino; William B Kannel; Ramachandran S Vasan
Journal:  Eur J Heart Fail       Date:  2010-08       Impact factor: 15.534

5.  Circulating levels of soluble klotho and FGF23 in X-linked hypophosphatemia: circadian variance, effects of treatment, and relationship to parathyroid status.

Authors:  Thomas O Carpenter; Karl L Insogna; Jane H Zhang; Bruce Ellis; Sherril Nieman; Christine Simpson; Elizabeth Olear; Caren M Gundberg
Journal:  J Clin Endocrinol Metab       Date:  2010-08-04       Impact factor: 5.958

6.  Circulating fibroblast growth factor-23 is associated with fat mass and dyslipidemia in two independent cohorts of elderly individuals.

Authors:  Majd A I Mirza; Johan Alsiö; Ann Hammarstedt; Reinhold G Erben; Karl Michaëlsson; Asa Tivesten; Richard Marsell; Eric Orwoll; Magnus K Karlsson; Osten Ljunggren; Dan Mellström; Lars Lind; Claes Ohlsson; Tobias E Larsson
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-10-21       Impact factor: 8.311

7.  Vitamin D status and outcomes in heart failure patients.

Authors:  Licette C Y Liu; Adriaan A Voors; Dirk J van Veldhuisen; Eveline van der Veer; Anne M Belonje; Mariusz K Szymanski; Herman H W Silljé; Wiek H van Gilst; Tiny Jaarsma; Rudolf A de Boer
Journal:  Eur J Heart Fail       Date:  2011-05-04       Impact factor: 15.534

8.  Vitamin D status: United States, 2001-2006.

Authors:  Anne C Looker; Clifford L Johnson; David A Lacher; Christine M Pfeiffer; Rosemary L Schleicher; Christopher T Sempos
Journal:  NCHS Data Brief       Date:  2011-03

9.  Serum phosphorus levels associate with coronary atherosclerosis in young adults.

Authors:  Robert N Foley; Allan J Collins; Charles A Herzog; Areef Ishani; Philip A Kalra
Journal:  J Am Soc Nephrol       Date:  2008-11-05       Impact factor: 10.121

10.  Diets with high or low protein content and glycemic index for weight-loss maintenance.

Authors:  Thomas Meinert Larsen; Stine-Mathilde Dalskov; Marleen van Baak; Susan A Jebb; Angeliki Papadaki; Andreas F H Pfeiffer; J Alfredo Martinez; Teodora Handjieva-Darlenska; Marie Kunešová; Mats Pihlsgård; Steen Stender; Claus Holst; Wim H M Saris; Arne Astrup
Journal:  N Engl J Med       Date:  2010-11-25       Impact factor: 91.245

View more
  7 in total

Review 1.  Roles of phosphate and fibroblast growth factor 23 in cardiovascular disease.

Authors:  Julia J Scialla; Myles Wolf
Journal:  Nat Rev Nephrol       Date:  2014-04-01       Impact factor: 28.314

Review 2.  Dietary Phosphorus Intake and the Kidney.

Authors:  Alex R Chang; Cheryl Anderson
Journal:  Annu Rev Nutr       Date:  2017-06-14       Impact factor: 11.848

3.  Phosphorus Additives and Albuminuria in Early Stages of CKD: A Randomized Controlled Trial.

Authors:  Alex R Chang; Edgar R Miller; Cheryl A Anderson; Stephen P Juraschek; Melissa Moser; Karen White; Bobbie Henry; Caitlin Krekel; Susan Oh; Jeanne Charleston; Lawrence J Appel
Journal:  Am J Kidney Dis       Date:  2016-11-16       Impact factor: 8.860

Review 4.  The role of phosphate in kidney disease.

Authors:  Marc G Vervloet; Siren Sezer; Ziad A Massy; Lina Johansson; Mario Cozzolino; Denis Fouque
Journal:  Nat Rev Nephrol       Date:  2016-11-21       Impact factor: 28.314

5.  Obesity-Related Oxidative Stress: the Impact of Physical Activity and Diet Manipulation.

Authors:  Chun-Jung Huang; Matthew J McAllister; Aaron L Slusher; Heather E Webb; J Thomas Mock; Edmund O Acevedo
Journal:  Sports Med Open       Date:  2015-09-23

6.  Changes in fibroblast growth factor 23 levels in normophosphatemic patients with chronic kidney disease stage 3 treated with lanthanum carbonate: results of the PREFECT study, a phase 2a, double blind, randomized, placebo-controlled trial.

Authors:  Pablo Ureña-Torres; Dominique Prié; Karim Keddad; Peter Preston; Paul Wilde; Hong Wan; J Brian Copley
Journal:  BMC Nephrol       Date:  2014-05-05       Impact factor: 2.388

7.  Examining the effects of uric acid-lowering on markers vascular of calcification and CKD-MBD; A post-hoc analysis of a randomized clinical trial.

Authors:  Emily S Andrews; Loni Perrenoud; Kristen L Nowak; Zhiying You; Andreas Pasch; Michel Chonchol; Jessica Kendrick; Diana Jalal
Journal:  PLoS One       Date:  2018-10-24       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.